{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T01:11:31Z","timestamp":1793927491705,"version":"4.8.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,2,3]],"date-time":"2015-02-03T00:00:00Z","timestamp":1422921600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1007\/s40272-014-0116-y","type":"journal-article","created":{"date-parts":[[2015,2,2]],"date-time":"2015-02-02T16:26:08Z","timestamp":1422894368000},"page":"159-166","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["Long-Term Statin Treatment in Children with Familial Hypercholesterolemia: More Insight into Tolerability and Adherence"],"prefix":"10.1007","volume":"17","author":[{"given":"Marjet J. A. M.","family":"Braamskamp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Meeike","family":"Kusters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans J.","family":"Avis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen M. A.","family":"Smets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frits A.","family":"Wijburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J. P.","family":"Kastelein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Wiegman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara A.","family":"Hutten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,2,3]]},"reference":[{"issue":"1","key":"116_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0021-9150(02)00330-1","volume":"168","author":"D Marks","year":"2003","unstructured":"Marks D, Thorogood M, Neil HAW, Humphries SE. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis. 2003;168(1):1\u201314.","journal-title":"Atherosclerosis."},{"key":"116_CR2","unstructured":"Goldstein JL, Hobbs HH, Brown MS. PART 12: LIPIDS Chapter 120: Familial Hypercholesterolemia Joseph L. Goldstein, Helen H. Hobbs, Michael S. Brown. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The Metabolic and Molecular Bases of Inherited Disease. 8th ed.; 2001. p. 2863\u20132913."},{"issue":"suppl 1","key":"116_CR3","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1159\/000329163","volume":"76","author":"SR Daniels","year":"2011","unstructured":"Daniels SR. Screening and treatment of dyslipidemias in children and adolescents. Horm Res Paediatr. 2011;76(suppl 1):47\u201351. doi: 10.1159\/000329163 .","journal-title":"Horm Res Paediatr."},{"issue":"14","key":"116_CR4","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1161\/CIRCULATIONAHA.107.181946","volume":"115","author":"BW McCrindle","year":"2007","unstructured":"McCrindle BW, Urbina EM, Dennison BA, et al. Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the C. Circulation. 2007;115(14):1948\u201367.","journal-title":"Circulation."},{"issue":"10","key":"116_CR5","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1001\/jama.2014.8892","volume":"312","author":"DM Kusters","year":"2014","unstructured":"Kusters DM, Avis HJ, de Groot E, et al. Ten-year follow-up after initiation of statin therapy in children with familial hypercholesterolemia. JAMA. 2014;312(10):1055\u20137. doi: 10.1001\/jama.2014.8892 .","journal-title":"JAMA."},{"issue":"23","key":"116_CR6","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1161\/CIRCULATIONAHA.108.768986","volume":"119","author":"PM Ho","year":"2009","unstructured":"Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009;119(23):3028\u201335.","journal-title":"Circulation."},{"issue":"2","key":"116_CR7","doi-asserted-by":"crossref","first-page":"e9220","DOI":"10.1371\/journal.pone.0009220","volume":"5","author":"R Huijgen","year":"2010","unstructured":"Huijgen R, Kindt I, Verhoeven SBJ, et al. Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal. PLoS One. 2010;5(2):e9220.","journal-title":"PLoS One."},{"issue":"5","key":"116_CR8","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMra050100","volume":"353","author":"L Osterberg","year":"2005","unstructured":"Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487\u201397.","journal-title":"N Engl J Med."},{"issue":"1","key":"116_CR9","doi-asserted-by":"crossref","first-page":"36","DOI":"10.2337\/diacare.20.1.36","volume":"20","author":"M Kovacs","year":"1997","unstructured":"Kovacs M, Goldston D, Obrosky DS, Bonar LK. Psychiatric disorders in youths with IDDM: rates and risk factors. Diabetes Care. 1997;20(1):36\u201344.","journal-title":"Diabetes Care."},{"issue":"1","key":"116_CR10","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/QAI.0b013e318199072e","volume":"51","author":"JB Nachega","year":"2009","unstructured":"Nachega JB, Hislop M, Nguyen H, et al. Antiretroviral therapy adherence, virologic and immunologic outcomes in adolescents compared with adults in southern Africa. J Acquir Immune Defic Syndr. 2009;51(1):65\u201371.","journal-title":"J Acquir Immune Defic Syndr."},{"issue":"1","key":"116_CR11","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jadohealth.2004.09.013","volume":"38","author":"GN Zindani","year":"2006","unstructured":"Zindani GN, Streetman DD, Streetman DS, Nasr SZ. Adherence to treatment in children and adolescent patients with cystic fibrosis. J Adolesc Health. 2006;38(1):13\u20137.","journal-title":"J Adolesc Health."},{"issue":"3","key":"116_CR12","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1001\/jama.292.3.331","volume":"292","author":"A Wiegman","year":"2004","unstructured":"Wiegman A, Hutten BA, de Groot E, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA. 2004;292(3):331\u20137. doi: 10.1001\/jama.292.3.331 .","journal-title":"JAMA."},{"issue":"6","key":"116_CR13","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","volume":"18","author":"WT Friedewald","year":"1972","unstructured":"Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499\u2013502.","journal-title":"Clin Chem."},{"issue":"6","key":"116_CR14","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s10557-004-6225-z","volume":"18","author":"V Senior","year":"2004","unstructured":"Senior V, Marteau TM, Weinman J. Self-reported adherence to cholesterol-lowering medication in patients with familial hypercholesterolaemia: the role of illness perceptions. Cardiovasc Drugs Ther. 2004;18(6):475\u201381.","journal-title":"Cardiovasc Drugs Ther."},{"issue":"4","key":"116_CR15","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S1081-1206(10)60532-7","volume":"103","author":"JL Cohen","year":"2009","unstructured":"Cohen JL, Mann DM, Wisnivesky JP, et al. Assessing the validity of self-reported medication adherence among inner-city asthmatic adults: the Medication Adherence Report Scale for Asthma. Ann Allergy Asthma Immunol. 2009;103(4):325\u201331.","journal-title":"Ann Allergy Asthma Immunol."},{"issue":"6","key":"116_CR16","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/ibd.20846","volume":"15","author":"R Horne","year":"2009","unstructured":"Horne R, Parham R, Driscoll R, Robinson A. Patients\u2019 attitudes to medicines and adherence to maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis. 2009;15(6):837\u201344.","journal-title":"Inflamm Bowel Dis."},{"key":"116_CR17","doi-asserted-by":"crossref","first-page":"d12","DOI":"10.1136\/bmj.d12","volume":"342","author":"KJL Bell","year":"2011","unstructured":"Bell KJL, Kirby A, Hayen A, Irwig L, Glasziou P. Monitoring adherence to drug treatment by using change in cholesterol concentration: secondary analysis of trial data. BMJ. 2011;342:d12.","journal-title":"BMJ."},{"issue":"9493","key":"116_CR18","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","volume":"366","author":"C Baigent","year":"2005","unstructured":"Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267\u201378.","journal-title":"Lancet."},{"issue":"13","key":"116_CR19","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1001\/jama.289.13.1681","volume":"289","author":"PD Thompson","year":"2003","unstructured":"Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA. 2003;289(13):1681\u201390.","journal-title":"JAMA."},{"issue":"6","key":"116_CR20","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","volume":"19","author":"E Bruckert","year":"2005","unstructured":"Bruckert E, Hayem G, Dejager S, Yau C, B\u00e9gaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients\u2014the PRIMO study. Cardiovasc Drugs Ther. 2005;19(6):403\u201314.","journal-title":"Cardiovasc Drugs Ther."},{"issue":"25","key":"116_CR21","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1161\/CIRCULATIONAHA.106.624890","volume":"114","author":"A Kashani","year":"2006","unstructured":"Kashani A, Phillips CO, Foody JM, et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation. 2006;114(25):2788\u201397.","journal-title":"Circulation."},{"issue":"10","key":"116_CR22","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s00228-009-0673-0","volume":"65","author":"S Perreault","year":"2009","unstructured":"Perreault S, Dragomir A, Blais L, et al. Impact of better adherence to statin agents in the primary prevention of coronary artery disease. Eur J Clin Pharmacol. 2009;65(10):1013\u201324.","journal-title":"Eur J Clin Pharmacol."},{"issue":"7","key":"116_CR23","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.amjmed.2009.01.032","volume":"122","author":"S Perreault","year":"2009","unstructured":"Perreault S, Ellia L, Dragomir A, et al. Effect of statin adherence on cerebrovascular disease in primary prevention. Am J Med. 2009;122(7):647\u201355.","journal-title":"Am J Med."},{"issue":"6","key":"116_CR24","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/j.1365-2125.2006.02828.x","volume":"63","author":"M-H Bouchard","year":"2007","unstructured":"Bouchard M-H, Dragomir A, Blais L, B\u00e9rard A, Pilon D, Perreault S. Impact of adherence to statins on coronary artery disease in primary prevention. Br J Clin Pharmacol. 2007;63(6):698\u2013708.","journal-title":"Br J Clin Pharmacol."},{"issue":"4","key":"116_CR25","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1001\/jama.288.4.455","volume":"288","author":"JS Benner","year":"2002","unstructured":"Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288(4):455\u201361.","journal-title":"JAMA."},{"issue":"4","key":"116_CR26","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1001\/jama.288.4.462","volume":"288","author":"CA Jackevicius","year":"2002","unstructured":"Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA. 2002;288(4):462\u20137.","journal-title":"JAMA."},{"issue":"9","key":"116_CR27","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s00228-005-0980-z","volume":"61","author":"S Perreault","year":"2005","unstructured":"Perreault S, Blais L, Dragomir A, et al. Persistence and determinants of statin therapy among middle-aged patients free of cardiovascular disease. Eur J Clin Pharmacol. 2005;61(9):667\u201374.","journal-title":"Eur J Clin Pharmacol."},{"issue":"9","key":"116_CR28","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1345\/aph.1P150","volume":"44","author":"DM Mann","year":"2010","unstructured":"Mann DM, Woodward M, Muntner P, Falzon L, Kronish I. Predictors of nonadherence to statins: a systematic review and meta-analysis. Ann Pharmacother. 2010;44(9):1410\u201321.","journal-title":"Ann Pharmacother."},{"issue":"6","key":"116_CR29","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jacl.2010.08.026","volume":"4","author":"RJ Simpson","year":"2010","unstructured":"Simpson RJ, Mendys P. The effects of adherence and persistence on clinical outcomes in patients treated with statins: a systematic review. J Clin Lipidol. 2010;4(6):462\u201371.","journal-title":"J Clin Lipidol."},{"issue":"3","key":"116_CR30","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jacl.2011.03.001","volume":"5","author":"AC Goldberg","year":"2011","unstructured":"Goldberg AC, Hopkins PN, Toth PP, et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011;5(3):133\u201340.","journal-title":"J Clin Lipidol."},{"issue":"1","key":"116_CR31","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.atherosclerosis.2009.09.014","volume":"209","author":"H Pijlmana","year":"2010","unstructured":"Pijlmana H, Huijgen R, Verhagen SN, et al. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands. Atherosclerosis. 2010;209(1):189\u201394.","journal-title":"Atherosclerosis."}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40272-014-0116-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-014-0116-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-014-0116-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T15:24:56Z","timestamp":1598714696000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40272-014-0116-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,3]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["116"],"URL":"https:\/\/doi.org\/10.1007\/s40272-014-0116-y","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,3]]}}}